Answers are grounded in this paper and cite their sources.
Background: Curcumin is a natural phenolic compound obtained from Curcuma longa, with proven human monoamine oxidase (MAO) inhibitory activity, but due to its poor oral bioavailability, blood-brain barrier permeability and extensive metabolism in the liver, it has never been recognized as a drug candidate. Purpose: In this study, the structure-based-drug design (SBDD) was adopted to incorporate the structural features of Curcumin with an aim to improve drug permeability and metabolic stability. Method: A series of ferulic amides (half portion of curcumin) (1-3) and curcumin based pyrazolinescompounds (4-6) were designed and Curcumintested for their membrane permeability and liver microsomal metabolic stability in a various animal in an in-vitro assay system. Conclusion: All the designed compounds showed a significant enhancement in permeability and metabolic stability is achieved through chemical modification.
No takes yet. Share an insight, caveat, or question.
Badavath et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: